Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: A case report

被引：21

作者：

Sato H. ^{[1
,2
]}

Kobayashi D. ^{[1
]}

Abe A. ^{[1
]}

Ito S. ^{[1
]}

Ishikawa H. ^{[1
]}

Nakazono K. ^{[1
]}

Murasawa A. ^{[1
]}

Kuroda T. ^{[2
]}

Nakano M. ^{[3
]}

Narita I. ^{[2
]}

机构：

[1] Department of Rheumatology, Niigata Rheumatic Center, 1-2-8 Honcho, Shibata City, Niigata

[2] Division of Clinical Nephrology and Rheumatology, Niigata University, Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata City, Niigata

[3] Department of Medical Technology, School of Health Sciences, Niigata University, 2-746 Asahimachi-Dori, Chuoku, Niigata City

来源：

BMC Research Notes | / 7卷 / 1期

关键词：

Interleukin-6; Multiple sclerosis; Rheumatoid arthritis; Tocilizumab; Tumour necrosis factor;

D O I：

10.1186/1756-0500-7-641

中图分类号：

学科分类号：

摘要：

Background: Multiple sclerosis is a relatively rare disease, and complications of multiple sclerosis and rheumatoid arthritis are much rarer. Since anti-tumor necrosis factor therapy increases exacerbations of multiple sclerosis, complications of demyelinating diseases contraindicate anti-tumor necrosis factor therapy. There have been few reports of anti-interleukin-6 receptor therapy for patients with rheumatoid arthritis complicated with multiple sclerosis. Case presentation. A 53-year-old Japanese woman with multiple sclerosis and rheumatoid arthritis was admitted to our hospital because her rheumatoid arthritis was uncontrolled with oral methotrexate, tacrolimus, and prednisolone. She had developed multiple sclerosis when she was 25 years old and was treated with glucocorticoid therapy. Her multiple sclerosis was in remission for more than 9 years. Because anti-tumour necrosis factor therapy can exacerbate demyelinating disease, the anti-interleukin-6 receptor antibody tocilizumab was started at 8 mg/kg every 4 weeks. At the second administration of tocilizumab, complete remission was achieved. She has remained in remission with tocilizumab without recurrence of multiple sclerosis for more than 5 years. Conclusion: Anti-interleukin-6 therapy was safely used in this patient with rheumatoid arthritis without exacerbations of multiple sclerosis. © 2014Sato et al.; licensee BioMed Central Ltd.

引用

共 15 条

[1] Sharief M.K., Hentges R., Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis, N Engl J Med, 325, pp. 467-472, (1991)
[2] TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study, Neurology, 53, pp. 457-465, (1999)
[3] Van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., Von Blomberg B.M., Woody J.N., Hartung H.P., Polman C.H., Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2, Neurology, 47, pp. 1531-1534, (1996)
[4] Attout H., Toussirot E., Auge B., Chavot D., Wendling D., Rheumatoid arthritis and multiple sclerosis in the same patient. Two case-reports, Rev Rhum Engl Ed, 66, pp. 169-172, (1999)
[5] Mpofu S., Moots R.J., A case of multiple sclerosis associated with rheumatoid arthritis and positive anticardiolipin antibodies, Ann Rheum Dis, 62, (2003)
[6] Fromont A., De Seze J., Fleury M.C., Maillefert J.F., Moreau T., Inflammatory demyelinating events following treatment with anti-tumor necrosis factor, Cytokine, 45, pp. 55-57, (2009)
[7] Lozeron P., Denier C., Lacroix C., Adams D., Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy, Arch Neurol, 66, pp. 490-497, (2009)
[8] Tristano A.G., Neurological adverse events associated with anti-tumor necrosis factor alpha treatment, J Neurol, 257, pp. 1421-1431, (2010)
[9] Levesque M.C., Ward F.E., Jeffery D.R., Weinberg J.B., Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1∗0404 allele, Arthritis Rheum, 42, pp. 569-573, (1999)
[10] Nakatsuji Y., Nakano M., Moriya M., Kishigami H., Tatsumi C., Tada S., Sadahiro S., Naka T., Mitani K., Funauchi M., Azuma T., Watanabe S., Kinoshita M., Kajiyama K., Yuasa Y., Kaido M., Takahashi M.P., Naba I., Hazama T., Sakoda S., Neurological Research Consortium O., Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection, Cytokine, 36, pp. 69-74, (2006)

← 1 2 →